# Vaxart, Inc.: Form 10-Q for the period ended Mar 27, 2010

- Company: [Vaxart, Inc.](/companies/vxrt.md) (CIK 72444)
- Form: 10-Q
- Filed: 2010-05-06
- Accepted by EDGAR: May 6, 2010, 21:11 ET
- Period: 2010-03-27
- Accession: 0001193125-10-111125
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/72444/000119312510111125/d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/72444/000119312510111125/

## Management's discussion and analysis

As filed, 15,422 characters.

### FORWARD LOOKING STATEMENTS

*Statements in this quarterly report that are not strictly historical are forward-looking statements and include statements about products in development, results and analyses of clinical trials and studies, research and development expenses, cash expenditures, licensure applications and approvals, and alliances and partnerships, among other matters. You can identify these forward-looking statements because they involve our expectations, intentions, beliefs, plans, projections, anticipations, or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our ability to conduct and obtain successful results from our two Phase III clinical trials for NicVAX; GSK’s failure to exercise its option for and successfully commercialize NicVAX; GSK’s failure to successfully develop and commercialize any future generation candidate nicotine vaccine; our ability to commercialize NicVAX if GSK does not exercise its option for NicVAX; our ability to raise sufficient new capital resources to fully develop and commercialize NicVAX if GSK does not exercise the NicVAX option; our ability to attract, retain and motivate key employees; our ability to collect any further milestones and royalty payments under the PhosLo and PentaStaph agreements; the ability to obtain regulatory approval for NicVAX and any future generation candidate nicotine vaccine in the U.S. or other markets; our ability to successfully contract with contract manufacturing organizations for the manufacture and supply of NicVAX; our ability to comply with reporting and payment obligations under government rebate and pricing programs; and loss of full use of our net operating loss carry forwards. Some of these factors are more fully discussed, as are other factors, in our Annual Report on Form 10-K for the fiscal year ended December 26, 2009 filed with the Securities and Exchange Commission. We do not undertake to update any of these forward-looking statements or to announce the results of any revisions to these forward-looking statements except as required by law.*

The following is a discussion and analysis of the major factors contributing to our financial condition and results of operations for the three months ended March 27, 2010. The discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto.

### OVERVIEW

We are a biopharmaceutical company focused on the development of vaccines addressing unmet medical needs in the area of nicotine addiction. We leverage our experience and knowledge in powering the human immune system to target serious unmet medical needs in this area. Our lead product currently in development is NicVAX®, an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. On March 8, 2010 we entered into an option and license agreement for NicVAX and future generation smoking cessation vaccine(s) with GSK.

### Product Development

NicVAX is an investigational therapeutic vaccine for smoking cessation, based on patented technology. The smoking cessation market is estimated to exceed $4 billion annually and is currently considered to be a largely unmet medical need. Nicotine, a non-immunogenic small molecule, can, upon inhalation through smoking, cross the blood-brain barrier and reach specific receptors in the brain, causing the release of dopamine thereby leading to the highly addictive pleasure sensation experienced by smokers and users of nicotine products. NicVAX is designed to stimulate the immune system to produce highly specific antibodies that bind to nicotine. A nicotine molecule attached to an antibody is too large to cross the blood-brain barrier, and thus is unable to reach the receptors in the brain and trigger pleasure sensations. In November 2007, we announced the successful completion of a Phase IIb “proof-of-concept”

clinical trial for NicVAX that showed statistically significant rates of smoking cessation and continuous long-term smoking abstinence at 6 and 12 months for subjects injected with NicVAX as compared with subjects injected with placebo. In October 2008, we announced the results of a Phase II schedule optimization immunogenicity study assessing the antibody response and safety of a six-dose immunization schedule. This study showed that significantly higher antibody levels can be generated earlier in a higher percentage of subjects than in the Phase IIb proof-of-concept study and that the revised dose regimen continued to be well tolerated. These key results have supported the basis of our design for the NicVAX Phase III trials. In December 2008, we announced that we had reached agreement with the FDA on a SPA for the pivotal Phase III clinical trials for NicVAX. The SPA forms the foundation to support approval of a NDA. In June 2009, we announced that we received scientific advice from the EMEA which is well aligned with our SPA agreement with the FDA regarding the design of the trial. In September 2009, we announced that we received a $10 million grant from NIDA to partially offset the cost of the first of two Phase III studies that are required by the FDA in support of NicVAX’s licensure. In October 2009 we also announced the initiation of an investigator initiated clinical trial in the Netherlands to test the efficacy of a combined therapy of NicVAX with varenicline, or Chantix. In November 2009 we announced the initiation of the first of two Phase III efficacy trials in the U.S., and we initiated the second Phase III efficacy trial in March 2010. As such, NicVAX is at a more advanced stage of development than any potentially competing smoking cessation vaccine.

### Strategic Initiatives

Beginning in 2006 we initiated a strategic alternatives process to enhance shareholder value. This strategic alternatives process has resulted in the sale, licensure or grant of an option to acquire all of our marketed products and major pipeline products. Thus, PentaStaph was sold to GSK who also acquired an exclusive option and license agreement for NicVAX.

### RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 27, 2010 AND MARCH 28, 2009

*Revenue.* Revenue was $13.7 million for the first quarter of 2010; we had no revenue in 2009. Revenue in 2010 reflects amounts recognized under the PentaStaph and NicVAX agreements with GSK. This includes $4.6 million from the initial $21.5 million payment received from GSK for PentaStaph which is being recognized as revenue ratably over the term of the Joint Steering Committee, currently expected to be 14 months and $0.2 million from the initial $40 million payment received from GSK for NicVAX which is being recognized as revenue ratably over the term of the Joint Steering Committee, currently expected to be 190 months. We also recognized $8.0 million of revenue upon the successful achievement of a PentaStaph performance milestone and $0.9 million related to our services provided under the PentaStaph agreement. Our revenue over the remainder of 2010 will reflect ongoing ratable recognition of upfront payment, reimbursement by GSK of costs related to PentaStaph and possible achievement of the remaining PentaStaph milestones.

*Cost of services.* Cost of services of $0.7 million represents the cost incurred by us to perform under the PentaStaph agreement with GSK with respect to the transitional services, including performance of the Phase I clinical trial and associated activities. These costs include internal labor, external contractors and allocated indirect costs.

*General and administrative expenses*. General and administrative expenses were $1.8 million for the first quarter of 2010 compared to $3.1 million for the first quarter of 2009. The decrease of $1.3 million reflects our effort to reduce expenses, lower levels of legal and facilities costs as well as an allocation of a portion of these costs to cost of services. We expect our full-year 2010 general and administrative expenses to be below 2009.

*Research and development expenses*. Research and development expenses were $5.9 million for the first quarter of 2010 compared to $3.8 million for the first quarter of 2009. Research and development increased approximately $2.1 million primarily due to the ongoing first Phase III trial for NicVAX, start up of the second Phase III NicVAX trial and NicVAX manufacturing-related activities. The cost of the PentaStaph Phase I clinical trial will be reimbursed by GSK and $1.1 million of the costs for the NicVAX trial is being offset by grant funding from NIDA. Research and Development expenses are expected to increase during the balance of 2010.

*Interest expense.* Interest expense was $0.1 million and $0.4 million for the first quarters of 2010 and 2009, respectively and consisted largely of interest expense associated with our Convertible Senior Notes. The decrease in interest expense reflects the impact of a lower debt level in 2010 as compared to 2009.

### LIQUIDITY AND CAPITAL RESOURCES

Our cash, cash equivalents and marketable securities at March 27, 2010 totaled $158.1 million compared to $119.0 million at December 26, 2009. This increase is primarily the result of $55.4 million received from GSK associated with the PentaStaph and NicVAX agreements offset in part by our operating expenses along with the payments of approximately $9.6 million for the repurchases of our shares of common stock.

Cash provided by operating activities from continuing operations for the three months ended March 27, 2010 was $48.6 million, compared to cash used in operating activities of $6.5 million for the three months ended March 28, 2009. The increase in cash was primarily associated with the cash received of $55.4 million from GSK for the PentaStaph and NicVAX offset in part by cash used for general and administrative expenses and research and development expenses. Cash provided by investing activities for the three months ended March 27, 2010 was $49.1 million, consisting largely of the sales and maturities of our marketable securities.

In the first quarter of 2010, the Company purchased 1.8 million shares for $9.2 million at an average cost per share of $5.03. On March 29, 2010, our Board of Directors approved the repurchase of up to $60.9 million of our common stock in the open market or in privately negotiated transactions, including $10.9 million remaining from the $65 million repurchase program. Subsequent to quarter end, we repurchased an additional 3.6 million shares for $20.7 million, at an average price of $5.67 per share. Since the inception of the program in December 2007 through April 30, 2010, we repurchased a total of 17.6 million shares for a total cost of $74.8 million, at an average of $4.25 per share. Under the current program, $40.2 million remained available for share repurchase as of this date. Repurchased shares have been accounted for as treasury stock using the cost method.

We believe cash, cash equivalents and marketable securities on hand at March 27, 2010 will be sufficient to meet our anticipated cash requirements for operations for at least the next 12 months.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Note 2 to our condensed consolidated financial statements includes a discussion of our significant accounting policies. A summary of the more significant policies follows:

*Accounting estimates:* The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period, including such amounts related to discontinued operations. Actual results could differ from those estimates.

*Revenue recognition:* Our contracts and agreements may include multiple elements and deliverables, including licenses, options, research and development activities, participation on joint steering committees, and contract manufacturing, among other elements. When we determine that a multiple element has stand alone value to our customer, we allocate the total contract price to that element based on its objectively determined and relative fair value, and recognize revenue for that element according to its characteristics. When we cannot reliably and objectively determine fair values of any delivered element, we combine that element with undelivered elements and recognize revenue as a single unit of accounting. Revenues related to substantive milestone activities are recognized as revenue in the period such activities are completed.

We analyze cost reimbursable grants and contracts to determine whether we should report such reimbursements as revenue or as an offset to our expenses incurred. For the three months ended March 27, 2010, the Company recorded approximately $1.1 million of such cost reimbursements as an offset to research and development expenses (none for the three months ended March 28, 2009).

*Research and development expenses:* Research and development costs are expensed as incurred; advanced payments are deferred and amortized over the period of performance. We use our research and development resources, including employees, equipment and facilities, across multiple drug development programs. Research and development expenses include direct labor costs as well as the costs of contractors and other direct and indirect expenses (including an allocation of the costs of facilities). We expense amounts payable to third parties under collaborative product development agreements at the earlier of the milestone achievement or as payments become contractually due. In circumstances where we receive grant income (which is a reimbursement to research and development costs incurred), we record the income as an offset to the related expense.

*Share-based compensation*: We currently account for share-based compensation at fair value; accordingly we expense the estimated fair value of share-based awards made in exchange for employee services over the requisite employee service period. Share-based compensation cost is determined at the grant date using an option pricing model. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee’s requisite service period.

*New accounting pronouncements:* There are several new accounting and disclosure requirements that we will be required to adopt in the future, primarily with respect to revenue recognition practices. In 2011 we will be required to adopt new revenue recognition practices relating to revenue arrangements that include multiple elements. Our license agreements with GSK related to our PentaStaph and NicVAX products may be affected by the new accounting and disclosure requirements. We are currently evaluating any potential impact these new requirements may have on our consolidated financial statements.

## Market risk

As filed, 220 characters.

There have been no material changes to our market risk as described in Item 7A of our Annual Report on Form 10-K for the year ended December 26, 2009. We repurchased all of our Convertible Senior Notes on April 15, 2010.

## Controls and procedures

As filed, 2,757 characters.

Our Chief Executive Officer currently serves as acting Chief Financial Officer.

As of the end of the period covered by this Quarterly Report, management performed, with the participation of our Chief Executive Officer and Chief Accounting Officer, an evaluation of the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934, as amended (the Exchange Act), Rules 13a-15(e) and 15d-15(e)). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Accounting Officer, to allow timely decisions regarding required disclosures. Based on this evaluation, management, including our Chief Executive Officer and Chief Accounting Officer, has concluded that as of March 27, 2010, the Company’s disclosure controls and procedures were effective.

Management has identified several changes in our internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during 2010 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting, including changes with respect to our process for accruing clinical trial costs and recognizing revenue on multiple element arrangements. We are in the process of completing, but have not yet completed, our internal documentation of all the changes in our internal controls over financial reporting. To specifically address the changes identified in our internal controls over financial reporting, we developed and performed additional analytical and substantive procedures during our quarter closing process. Management believes that these additional procedures provide reasonable assurance that our condensed consolidated financial statements as of and for the three months ended March 27, 2010, are fairly stated in all material respects in accordance with generally accepted accounting principles in the United States.

A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met, and therefore, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. We do not expect that our disclosure controls and procedures or our internal control over financial reporting are able to prevent with certainty all errors and all fraud.

## Risk factors

As filed, 148 characters.

There have been no material changes to the Risk Factors contained in Item 1A of our Annual Report on Form 10-K for the year ended December 26, 2009.

Filed May 6, 2010.
Source: SEC EDGAR, the filing index for accession 0001193125-10-111125. Last ingested by Listed: Nov 5, 2026, 18:48 ET. No prices; not investment advice.
